νλλ‘μμΉ΄λ₯΄λ°λ―Έλ (νλλ‘μμ°λ μ)
νλλ‘μμΉ΄λ₯΄λ°λ―Έλ(μΌλ°μ μΌλ‘ νλλ‘μμ°λ μλ‘ μλ €μ§)λ λμ¬κΈΈνμ± νμ’ μμ μ λλ€. μμνμμλ μ£Όλ‘ μ§μ± μ νꡬ μ¦κ°μ¦ λ° λ°±νλ³κ³Ό κ°μ 골μ μ¦μμ± μ§νμ μΉλ£, λΉλ§μΈν¬μ’ λ° κ° μλ§μ’ μ 보쑰 μΉλ£μ μ¬μ©λ©λλ€. > **κ²½κ³ **: μ΄ μ½μ μΈν¬λ μ± μ½λ¬Όμ λλ€. μΈμ²΄ λ ΈμΆμ λ°©μ§νκΈ° μν΄ μ격ν μμ λ° μ·¨κΈ νλ‘ν μ½μ λ°λΌμΌ ν©λλ€. **μμ ν**: κ³ μμ΄λ νλλ‘μμΉ΄λ₯΄λ°λ―Έλμ 골μ μ΅μ ν¨κ³Όμ ν¨μ¬ λ λ―Όκ°νλ―λ‘ μ΄κΈ° μ§μ€μ μΈ λͺ¨λν°λ§μ΄ νμν©λλ€.
μμ© κΈ°μ : Hydroxycarbamide inhibits the enzyme **ribonucleotide reductase** β prevents the conversion of ribonucleotides to deoxyribonucleotides β depletes the intracellular pool of precursors essential for **DNA synthesis and repair**. It is a cell-cycle specific agent acting primarily in the **S-phase**, but it may also arrest cells at the G1-S border.
λλ¬Ό μ’ λ³ μ©λ
- Polycythaemia vera, chronic myeloid leukaemia, mast cell tumours, meningiomas Β· See Appendix for chemotherapy protocols Β· PO Β· variable Β· Reduce dosage frequency once in remission Β· Perform haematology initially weekly for one month, then every two weeks for one month, then monthly if tolerated.
- Polycythaemia vera, chronic myeloid leukaemia Β· See Appendix for chemotherapy protocols Β· PO Β· variable Β· Reduce dosage frequency once in remission Β· Haematology MUST be monitored weekly at the start of drug therapy due to greater risk of myelosuppression.
μ©λμ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μ°Έκ³ μλ£μ λλ€. νμ μ΅μ λΌλ²¨κ³Ό κ°λ³ νμμ λν΄ νμΈνμμμ€.
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Pre-existing bone marrow suppression
μ΄μλ°μ
- Myelosuppression (dose-limiting)
- Nausea
- Vomiting
- Diarrhoea
- Anorexia
- Dysuria
- Stomatitis
- Sloughing of nails
- Alopecia
- Methaemoglobinaemia (in cats at high doses)
- Cardiovascular changes (increased diastolic BP/HR, decreased systolic BP)
μ½λ¬Ό μνΈμμ©
- Other myelosuppressive agents Β· Increased risk of severe bone marrow suppression Β· major
λͺ¨λν°λ§
- Haematology (weekly for 1 month, then biweekly for 1 month, then monthly)
- Renal function parameters
- Blood pressure and ECG (due to potential cardiovascular effects)
κ³Όμ©λ
In cats, very high doses (>500 mg) have been reported to cause **methaemoglobinaemia**.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.